Biopharma companies can't consistently meet Annex 1 expectations. At the heart of the problems, regulators have shifted the burden of proof to manufacturers.
- Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
- Where Contamination Control Really Breaks Down In Practice
- Trends In FDA FY 2025 Warning Letters
- SUS Interchangeability Assessment And Qualification Best Practices
- 5 QMS Blind Spots You Should Know About
- New MIT Consortium Links Innovation With Real-World Biomanufacturing
- The Hidden Engineering Behind Successful Upstream Bioprocessing
GUEST COLUMNISTS
-
Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.
-
Where Contamination Control Really Breaks Down In Practice
Contamination control gaps arise when two dynamics merge — when processes become familiar and workloads increase. Here's how to spot them before they spin out of control.
-
Trends In FDA FY 2025 Warning Letters
The FDA issued a total of 303 warning letters to drug and biologics products in Fiscal Year 2025 (FY25), an increase from FY24. This article reveals key agency focal points and trends.
-
SUS Interchangeability Assessment And Qualification Best Practices
Establishing a robust single-use systems (SUS) interchangeability program can be a pivotal feature of a supply chain resiliency initiative.
-
5 QMS Blind Spots You Should Know About
Companies often underestimate the complexity of standing up an eQMS. These are five of the most common issues that lead to regulatory and GMP exposure risk.
-
New MIT Consortium Links Innovation With Real-World Biomanufacturing
In one area, the Initiative for New Manufacturing is exploring whether microfactories, championed by the EV industry, can help biopharma iterate facility design faster.
-
The Hidden Engineering Behind Successful Upstream Bioprocessing
In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
BIOSIMILAR WHITE PAPERS
-
Advancing A LNP Formulation To Clinical And Commercial Manufacturing
Lipid selection impacts the final LNP drug product and the LNP process. Review critical quality considerations for lipids and the process requirements for successful commercial-scale manufacturing.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
-
The Evolution Of Antibody-Drug Manufacturing6/3/2024
Explore how ADC chemistry and manufacturing have evolved, the challenges this dynamic growth has created, and how CDMOs are adapting to these changes to meet customer needs, now and in the future.
-
Achieve Higher Targeted Concentrations9/30/2025
Single-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development9/23/2025
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
BIOSIMILAR APP NOTES & CASE STUDIES
- Cell Culture Media Filtration: Evaluating Cell Culture Performance
- Developing A Large-Scale Tangential Flow Filtration Process
- Performance Of Mobius® Bag Assemblies With Ultimus® Film In Truck Shipping Simulation Test
- Accelerate Process Development With Automated Aseptic Sampling
- Overcoming The Solubility Challenges Of Antibody-Drug Conjugates
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- 3PBIOVIAN And INC Partner To Expand Access To Oncology Treatments In Colombia Through Biosimilar Development
- Celltrion Set To Benefit From Global Biosimilar Regulatory Streamlining, Driving Economies Of Scale From Development To Manufacturing And Direct Sales
- Celltrion Launches Remsima IV Liquid Formulation In Europe, Securing New Competitiveness To Lead The Global infliximab Market
- AAM And Biosimilars Council Laud FDA Plan To Streamline Biosimilar Medicines Development And Lower Costs For Patients
- Gannet BioChem Files Type II Drug Master File For mPEG Propionaldehyde 20K To Support Pegfilgrastim Biosimilars
- FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised By Professor Niazi: Further Cutting Development Costs By Up to 50%
- mAbxience Selects Genedata Bioprocess To Automate End-To-End CDMO Workflows
- Sandoz Creates New Global Biosimilar Development, Manufacturing And Supply Unit, Appoints Industry Veteran Armin Metzger To Lead Next Phase Of Growth
NEWSLETTER ARCHIVE
- 03.19.26 -- Struggling with mAb aggregation and other impurities?
- 03.19.26 -- A Novel In Vitro Glycosylation Approach For Difficult PTMs
- 03.05.26 -- Phase-Appropriate Control Lessons For mAb/ADC Manufacturers
- 02.26.26 -- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- 02.19.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?